Company: INMB
Filing Date: 2025-06-16
Form Type: S-8
Source: 0001213900-25-054428
Chunk: 8

Company: Inmune Bio, Inc.
Filing Date: 2025-06-16
Form: S-8
Chunk 8
---
 the SEC.

Our business, prospects,
financial condition, or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that
we currently consider immaterial. The trading price of our common stock could decline due to any of these risks, and, as a result, you
may lose all or part of your investment. The risks we have described also include forward-looking statements, and our actual results may
differ substantially from those discussed in these forward-looking statements. See “Cautionary Note Regarding Forward-Looking Statements.”

<div align='center'>2

DETERMINATION OF OFFERING PRICE</div>

The selling stockholders
will determine at what price they may sell the shares of common stock offered hereby, and such sales may be made at prevailing market
prices or at privately negotiated prices. See “Plan of Distribution” below for more information.

<div align='center'>USE OF PROCEEDS</div>

The shares of common stock offered hereby are being registered for the account of the selling stockholders named in this reoffer prospectus. All proceeds from the resale of the shares of common stock by the selling stockholders will go to the selling stockholders and we will not receive any proceeds from such resale. However, we will receive the cash exercise price if any of the selling stockholders exercise their options for common stock on a cash basis. We intend to use the net proceeds, if any, for working capital or general corporate purposes. We have agreed to pay the expenses of registration of these shares.

<div align='center'>SELLING STOCKHOLDERS</div>

This offering relates to the resale by the selling stockholders who have received or acquired, or may hereafter receive or acquire, the shares pursuant to the2017 Plan and 2019 Plan. The selling stockholders may resell all, a portion, or none of the shares of common stock from time to time.

The following table sets forth, based on information
provided to us by the selling stockholders or known to us, the name of each selling stockholder, the nature of any position, office or
other material relationship, if any, which the selling stockholder has had, within the past three years, with us or with any of our predecessors
or affiliates, and the number of shares of our common stock beneficially owned by the selling stockholder before this offering. Except
as otherwise indicated, the selling stockholders are past or present employees, directors or consultants of the Company. The